TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
The clinical trial will be conducted at 19 sites with 10,335 participants across India
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Phase III ARANOTE trial met primary endpoint, significantly increasing radiological progression-free survival (rPFS) with NUBEQA plus androgen deprivation therapy (ADT) compared to placebo plus ADT
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Subscribe To Our Newsletter & Stay Updated
